Search

ObjectiveThis study compared the post-activation performance enhancement (PAPE) effects of a flywheel eccentric overload (FEOL) exercise and barbell half squats (BHS) on countermovement jump (CMJ) and 30 m sprint performance.MethodsTwelve male collegiate competitive basketball players were enrolled in this study and they implemented two training protocols: barbell half squat (BHS) and flywheel eccentric overload (FEOL) training. The BHS protocol included three intensities of load: low (40% 1RM), medium (60% 1RM), and high (80% 1RM), with each intensity consisting of 5 sets of 3 repetitions. The FEOL protocol included three inertia intensities: low (0. 015 kg∙m2), medium (0.035 kg∙m2), and high (0.075 kg∙m2), with each intensity consisting of 3 sets of 6 repetitions. The measurement time points were before training (baseline) and at 3, 6, 9, and 12 minutes after training. A two-stage (stage-I and stage-II) randomized crossover design was used to determine the acute effects of both protocols on CMJ and sprint performance.ResultsAt each training intensity, the jump height, jump peak power output (PPO), jump impulse and 30m sprint speed at 3, 6, 9, and 12 minutes after BHS and FEOL training did not change significantly compared to the baseline. A 2-way ANOVA analysis indicated significant main effects of rest intervals on jump height, jump PPO, and jump impulse, as well as 30m sprint speed. The interaction of the Time × protocol showed a significant effect on jump height between BHS and FEOL groups at high intensity in stage-I (F = 3.809, p = 0.016, df = 4) and stage-II (F = 3.044, p = 0.037, df = 4). And in high training intensity, the jump height at 3 (7.78 ± 9.90% increase, ES = 0.561), 6 (8.96 ± 12.15% increase, ES = 0.579), and 9 min (8.78 ± 11.23% increase, ES = 0.608) were enhanced in I-FEOL group compared with I-BHS group (F = 3.044, p = 0.037, df = 4). In stage-II, the impulse and sprint speed of the FEOL group were significantly higher than those of the BHS group at 6, 9, and 12 min under low (FEOL = 0.015kg∙m2, BHS = 40%1RM), medium(FEOL = 0.035kg∙m2, BHS = 60%1RM), and high (FEOL = 0.075kg∙m2, BHS = 80%1RM) intensities. Furthermore, the sprint speed of the two training protocols did not change at different time points. The interaction of Time × training intensity showed lower sprint speeds in the II-BHS group at a high intensity (BHS = 80%1RM) compared to low (BHS = 40%1RM) and medium (BHS = 60%1RM) training intensities, especially at 9 min and 12 min rest intervals.ConclusionAlthough barbell half squat training and flywheel eccentric overload training did not provide a significant PAPE effect on explosive power (CMJ and sprint) in male basketball players, FEOL training showed a better potential effect on enhanced CMJ jump performance at the high training intensity.

Tumor infiltrating lymphocytes (TIL) reflect the host's anti-tumor immune response, and can be a valuable predictor of prognosis. However, many properties of TIL are not fully understood. In the present study, TCR-Vβ repertoires of cancer patients were primarily analyzed by flow cytometry. Abnormally expressed TCR-Vβ subfamilies were generally found in both TIL and peripheral blood lymphocytes (PBL) of each patient. Of note, increased patient age was associated with increasingly biased TCR-Vβ repertoire in TIL but not in PBL, and the dispersion degree of the differences of TCR-Vβ subfamilies between TIL and PBL correlated positively with age (P = 0.007). Utilizing immunoscope analysis, we identified the age-related reduction in TCR-Vβ diversity, but polyclonal pattern was predominant in significantly expanded TCR-Vβ subfamilies. In addition, we found that older patients possessed a decreased ratio of CD8+CD62L+ non-effector cells in TIL compared to PBL, implying age-related increase of CD8+CD62L- effector cells in TIL. The colocalization analysis of CD8 and CD3, however, suggested the suppressed activity of these effector cells in tumor microenvironment. These findings further elucidate the properties of TIL, showing an increasing difference between TIL and PBL with age, which may provide insight for the development of effective immunotherapies for cancer patients of different ages.

Beclin 1, a key regulator of autophagy, has been found to be aberrantly expressed in a variety of human malignancies. Herein, we employed immunohistochemistry (IHC) to detect the protein expression of Beclin 1 in non-small cell lung cancer (NSCLC) and paired normal adjacent lung tissues, and analyzed its clinicopathological/prognostic significance in NSCLC. Receiver operating characteristic (ROC) curve analysis was utilized to determine a cutoff point (>2 VS. ≤ 2) for Beclin 1 expression in a training set (n = 105). For validation, the ROC-derived cutoff value was subjected to analysis of the association of Beclin 1 with patients' clinical characteristics and outcome in a testing set (n = 111) and the overall patient cohort (n = 216). Our data showed that Beclin 1 was significantly lower in NSCLC tissues compared with the adjacent normal tissues, negatively associating with tumor recurrence rate (65.8% VS 32.3%; p < 0.001). In the testing set and the overall patient cohort, low expression of Beclin 1 showed significantly inferior overall survival (OS) (p < 0.001) and progression-free survival (PFS) (p < 0.001) compared to high expression of Beclin 1. In the testing set and the overall patient cohort, the median duration of OS for patients with high and low expression of Beclin 1 was 108 VS. 24.5 months (p < 0.001) and 108 VS. 28 months (p < 0.001), respectively. Furthermore, low expression of Beclin 1 was also a poor prognostic factor within each stage of NSCLC patients. Multivariate analysis identified that Beclin 1 was an independent prognostic factor for NSCLC. Our findings in the present study provided evidence that Beclin 1 may thus emerge as an independent prognostic biomarker in this tumor entity in the future.

Recent studies showed that incomplete cell reprogramming can transform cells into tumour-like cells. Lin28A is associated with fibroblast and sarcoma cell reprogramming, whereas its homologue Lin28B is associated with hematopoietic cell reprogramming. This study aimed to investigate the expression and prognostic difference between Lin28A and Lin28B in oral squamous cell carcinoma (OSCC). Expression level was assessed by immunohistochemistry and staining location was confirmed by immunofluorescence. Prognostic values were analysed and compared by the Kaplan-Meier analysis and uni and multivariate Cox regression models. Besides, in vitro cell assays and in vivo nude mice xenograft were used to demonstrate the influence of increased Lin28B expression in OSCC. Lin28A and Lin28B expression increased in OSCC, and co-expression of Lin28A and Lin28B showed no significant association with patient prognosis. Kaplan-Meier analysis showed that patients with high Lin28B but not Lin28A expression had lower overall survival (OS) rates than those with low Lin28B expression. Further Univariate analysis showed that patients with increased Lin28B expression had shorter disease-free survival (DFS) and shorter OS, while multivariate analysis showed Lin28B overexpression with TNM stage predicted poor prognosis in patients with OSCC. Besides, stable expressing Lin28B in oral cancer cells promoted cell migration, invasion, colony formation, in vivo proliferation and increased the expression of cancer suppressor miRNA let-7 targeted genes IL-6, HMGA2, the EMT markers Snail and Twist, the angiogenesis inducer VEGF, and the apoptosis inhibitor Survivin. These combined results indicate that Lin28B is a novel marker for predicting prognosis in patients with OSCC and may be a therapeutic target.

Human endometrium is a high dynamic tissue that contains endometrial stromal stem cells (hESSCs). The hESSCs have been differentiated into a number of cell lineages. However, differentiation of hESSCs into megakaryocytes (MKs) has not yet been investigated. The aim of this study was to investigate the feasibility of MK generation from hESSCs and subsequent production of functional platelets (PLTs). In our study, hESSCs were cultured from endometrial stromal cells as confirmed by positive stromal cell specific markers (CD90 and CD29) and negative hematopoietic stem cell markers (CD45 and CD34) expression. Then, hESSCs were differentiated in a medium supplemented with thrombopoietin (TPO) for 18 days. The MK differentiation was analyzed by flow cytometry and confocal microscopy. The differentiation medium was collected for PLT production analysis by flow cytometry, transmission electron microscopy and functional measurements. Our results show: 1) MKs were successfully generated from hESSCs as identified by expression of specific markers (CD41a: 1 ± 0.09% and 39 ± 3.0%; CD42b: 1.2 ± 0.06% and 28 ± 2.0%, control vs. differentiation) accompanied with reduction of pluripotent transcription factors (Oct4 and Sox2) expression; 2) The level of PLTs in the differentiation medium was 16 ± 1 number/µl as determined by size (2-4 µm) and CD41a expression (CD41a: 1 ± 0.4% and 90±2.0%, control vs. differentiation); 3) Generated PLTs were functional as evidenced by the up-regulation of CD62p expression and fibrinogen binding following thrombin stimulation; 4) Released PLTs showed similar ultra-structure characteristics (alpha granules, vacuoles and dense tubular system) as PLTs from peripheral blood determined by electron microscopic analysis. Data demonstrate the feasibility of generating MKs from hESSCs, and that the generated MKs release functional PLTs. Therefore, hESSCs could be a potential new stem cell source for in vitro MK/PLT production.